Simplex Trading
ARQT icon

Simplex Trading’s Arcutis Biotherapeutics ARQT Stock Holding History

Simplex Trading’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$99K Buy
4,200
+200
+5% +$5.1K ﹤0.01% 5106
2025
Q4 		$116K Sell
4,000
-1,600
-29% -$41K ﹤0.01% 4847
2025
Q3 		$105K Sell
5,600
-2,400
-30% -$37.9K ﹤0.01% 5670
2025
Q2 		$112K Sell
8,000
-7,300
-48% -$102K ﹤0.01% 5117
2025
Q1 		$239K Sell
15,300
-12,000
-44% -$169K ﹤0.01% 4132
2024
Q4 		$380K Buy
27,300
+17,400
+176% +$191K ﹤0.01% 3826
2024
Q3 		$92K Sell
9,900
-8,300
-46% -$81.9K ﹤0.01% 5313
2024
Q2 		$169K Sell
18,200
-134,800
-88% -$1.22M ﹤0.01% 4814
2024
Q1 		$1.52M Buy
153,000
+125,000
+446% +$933K ﹤0.01% 2678
2023
Q4 		$90K Buy
28,000
+10,600
+61% +$28.8K ﹤0.01% 5490
2023
Q3 		$92K Sell
17,400
-5,400
-24% -$45.9K ﹤0.01% 5167
2023
Q2 		$217K Buy
22,800
+22,700
+22,700% +$252K ﹤0.01% 4203
2023
Q1 		$1K Buy
+100
New +$1.45K ﹤0.01% 8638
2022
Q4 		– Sell
-600
Closed -$11K – 9143
2022
Q3 		$11K Sell
600
-2,000
-77% -$45.3K ﹤0.01% 8120
2022
Q2 		$55K Sell
2,600
-5,500
-68% -$113K ﹤0.01% 6356
2022
Q1 		$156K Buy
8,100
+7,700
+1,925% +$130K ﹤0.01% 5511
2021
Q4 		$8K Sell
400
-600
-60% -$11.9K ﹤0.01% 9173
2021
Q3 		$26K Hold
1,000
– – ﹤0.01% 8189
2021
Q2 		$27K Buy
1,000
+991
+11,011% +$27.9K ﹤0.01% 8305
2021
Q1 		$26K Buy
+9
New +$281 ﹤0.01% 7234

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Simplex Trading's ARQT Position: Q2 2024 in Review

Simplex Trading sold out of Arcutis Biotherapeutics (ARQT) in Q2 2024, closing a stake of 25,795 shares — an estimated $233K sold.

Simplex Trading first reported a position in ARQT in Q1 2021 and held it in 7 quarters. The position peaked at $361K in Q2 2022. 186 funds tracked by Wall St. Rank hold ARQT as of Q2 2024.

  • Simplex Trading reported no remaining Arcutis Biotherapeutics position as of Q2 2024 after selling out during the quarter.
  • Simplex Trading sold 25,795 Arcutis Biotherapeutics shares in Q2 2024, an estimated $233K.
  • Simplex Trading first reported a position in Arcutis Biotherapeutics in Q1 2021 and held it in 7 quarters.
  • Simplex Trading's Arcutis Biotherapeutics position peaked at $361K in Q2 2022.
  • 186 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2024.

Based on Simplex Trading's 13F filing for Q2 2024, filed 25 Jul 2024.